
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MyD88 CRISPR/Cas9 KO Plasmid (m2) | sc-421774-KO-2 | 20 µg | $397.00 | |||
MyD88 HDR Plasmid (m2) | sc-421774-HDR-2 | 20 µg | $445.00 |
Myd88 encodes the adaptor protein MyD88, a central signaling node for most Toll-like receptors and members of the IL-1 receptor family in mouse innate immune cells. Upon receptor engagement, MyD88 assembles the myddosome with IRAK kinases and TRAF6 to drive NF-κB and MAPK activation and shape inflammatory cytokine and chemokine programs. This pathway influences dendritic cell and macrophage activation, antibody responses, and host defense to microbes, while also modulating sterile inflammation. Dysregulated MyD88-dependent signaling is implicated in inflammatory and autoimmune phenotypes, altered responses to infection, and tumor-associated inflammation in mouse models.
MyD88 CRISPR/Cas9 KO Plasmid (m2) is a pool of plasmids designed for targeted disruption of the Myd88 gene in mouse cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the Myd88 locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.
When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.
For applications requiring confirmed, selectable knockout clones, MyD88 HDR Plasmid (m2) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined Myd88 target site.
When co-transfected with MyD88 CRISPR/Cas9 KO Plasmid (m2):
The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the Myd88 locus and eliminating potential confounding effects on downstream assays.
This two-step approach:
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.